Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06119685 · ClinicalTrials.gov registry record · Phase 1
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
A Phase 1 study of Multiple Myeloma and Refractory Multiple Myeloma, sponsored by Indapta Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
- 12
- Study locations
NCT06119685: Recruiting Phase 1 study of Multiple Myeloma and Refractory Multiple Myeloma, sponsored by Indapta Therapeutics.
NCT06119685 is a Phase 1 study of Multiple Myeloma and Refractory Multiple Myeloma that is actively recruiting participants, run by Indapta Therapeutics. The registered enrollment target is 128 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (77% lower). The trial reports 12 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06119685, a Phase 1 study of Multiple Myeloma and Refractory Multiple Myeloma, is actively recruiting participants, sponsored by Indapta Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.
Primary Outcome
Escalation Period
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Rituximab
- DRUG Daratumumab
- DRUG Interleukin-2
- DRUG IDP-023
Study Locations (12)
California
- Valkyrie Clinical Trials - Los Angeles
Florida
- Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center - Lake Mary
Georgia
- Emory University Hospital - Atlanta
Minnesota
- University of Minnesota - Minneapolis
New York
- NYP/Weill Cornell Medical Center - New York
North Carolina
- Atrium Health Wake Forest Baptist - Winston-Salem
Ohio
- University Hospitals Cleveland - Cleveland
Oregon
- Providence Cancer Institute Franz Clinic - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2023-10-25 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 1 |
What NCT06119685 shows while recruiting
NCT06119685 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (77% lower).
The record links to 7 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06119685 lists 12 locations in 12 states (California, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT06119685 about?
NCT06119685 is a clinical study titled "IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers". This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and pre...
What is the current status of trial NCT06119685?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2023-10-25. Estimated completion is 2029-12-31.
What conditions does trial NCT06119685 study?
This clinical trial studies the following conditions: Multiple Myeloma, Refractory Multiple Myeloma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Blood Cancer.
What interventions are being tested in trial NCT06119685?
The interventions under investigation include: Cyclophosphamide (DRUG), Rituximab (DRUG), Daratumumab (DRUG), Interleukin-2 (DRUG), IDP-023 (DRUG).
Who is sponsoring clinical trial NCT06119685?
This trial is sponsored by Indapta Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06119685 being conducted?
This trial has 12 study locations across California, Florida, Georgia, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06119685's enrollment target sits among peer trials
128 146th of 438 higher than 293 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI